Previous 10 | Next 10 |
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will...
The shares of the development-stage biotech Ocugen (NASDAQ:OCGN) has added ~7% in the pre-market Monday after the company announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its Phase 2/3 clinical trial for COVID-19 shot, Covaxin. Covaxin, being de...
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) lifted the clinical h...
Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. Why? The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin ...
Ocugen (NASDAQ:OCGN) is trading lower in the pre-market Thursday after H.C. Wainwright cut its priced target on the clinical-stage biotech citing a potential delay in the launch of the company’s COVID-19 vaccine due to a production issue. During the recent earnings call, Ocugen (OCGN) ...
Ocugen (NASDAQ:OCGN) shares have dropped for the third straight trading session following the firm's Q1 earnings release last week that missed Wall Street estimates. Quarterly losses more than doubled to $18M from $7M in Q121. The results were impacted by increased R&D expenses, which gre...
Ocugen Reports 1Q22 Within Expectations. Ocugen reported a loss of $18.0 million or $(0.09) per share, larger than our expected loss of $15.8 million or $(0.06) per share. During the quarter, the company continued to work with US and Canadian regulators toward Covaxin approval. The Phase 1/2 O...
Ocugen, Inc. (OCGN) Q1 2022 Earnings Conference Call May 06, 2022 08:30 AM ET Company Participants Ken Inchausti - Head, Investor Relations & Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Jessica Crespo - Chief Accounting Officer & Senior Vice Pr...
Image source: The Motley Fool. Ocugen, Inc. (NASDAQ: OCGN) Q1 2022 Earnings Call May 06, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript
Ocugen press release (NASDAQ:OCGN): Q1 GAAP EPS of -$0.09 misses by $0.10. OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review. For further details see: Ocugen GAAP EPS of...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to ...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...